Treatment of hyperpigmentation disorders
DOI:
https://doi.org/10.66344/jpad.16.2.2006.850References
Pathak MA, Fitzpatrick TB, Nghiem P, Aghassi DS, eds. Sun-protective agents: formulations, effects, and side effects. In: Fitzpatrick Dermatology in General Medicine, New York: McGraw-Hill; 1993. p. 2742-60.
Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213-7.
Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995; 131: 1453-7.
Alena F, Dixon W, Thomas P, Jimbow K. Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-scysteaminylphenol in black and yellow hair follicles. J Invest Dermatol 1995; 104: 792-7.
Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermatitis 1998; 39: 86-7.
Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis 1995; 32: 9-13.
Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther 1996; 276: 765-9.
Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328: 1438-43.
Kimbrough-Grccn CK, Griffiths CE, Finkel LJ, ct al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol 1994; 130: 727-33.
Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehiclecontrolled, clinical trial. Br J Dermatol 1993; 129: 415-21.
Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; lll: 40-8.
Galderma laboratories. Data on file.
Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 2002; 29: 539-40.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
